KilgourMD Secures Series A Funding
KilgourMD, a company known for its dermatologist-developed hair growth products for thinning hair, has successfully closed its Series A funding round. The funding was led by Prelude Growth Partners, with additional participation from Willow Growth, Joyance Partners, and Able Partners. The exact amount of the funding has not been disclosed.
Company Overview
Founded in 2023 by Stanford-trained dermatologist Dr. James Kilgour, KilgourMD offers products aimed at reducing hair fall and stimulating hair follicle growth, with claims of reducing hair fall by 30% within two months and increasing follicle growth by 200%. The company emphasizes that its products have no known side effects, making them a safe choice for consumers looking to address hair thinning issues.
Leadership and Vision
Dr. James Kilgour, who serves as the company's CEO, has been inspired by personal experiences with hair loss in menopausal women, including his own mother. "KilgourMD was born out of seeing firsthand the experience of my mother, as well as countless patients, struggling with hair loss during menopause," he stated. The company has already seen significant consumer engagement, with a reported sale of a bottle of scalp serum every 20 seconds.
Board Additions
As part of the Series A round, Prelude Growth Partners’ Managing Partner, Alicia Sontag, will join KilgourMD’s Board of Directors. She will be joining alongside Dr. Kilgour, Deborah Benton of Willow Growth, and COO Dr. Alok Prasad.
Strategic Use of Funds
The newly acquired funds will be directed towards expanding KilgourMD's active ingredient pipeline and developing new product formulations. The company also plans to conduct additional clinical trials, particularly targeting underserved populations experiencing hair loss. This follows a successful clinical trial focusing on menopausal women, where 95% of participants noted reduced hair shedding within six weeks, and most achieved significant hair regrowth within four months. These findings are set to be published in the Journal of Drugs in Dermatology.
Future Directions
KilgourMD continues to position itself at the intersection of clinical dermatology and consumer hair care by addressing scalp aging as a primary cause of hair thinning. The company offers a range of products, including treatment serums, shampoos, and conditioners, and maintains a highly engaged customer base, with over one-third of its customers recommending its products to others.
This Series A round marks a significant milestone for KilgourMD as it seeks to expand its influence within the hair care industry, leveraging clinical research to support its product offerings.